P173 Modulatory therapy experience in patients with cystic fibrosis in Turkey: a multi-centre study

Pınar Ergenekon,Ela Erdem Eralp,Ayşe Ayzıt Kılınc Sakallı,Mürüvvet Cenk,Azer Kılıç Başkan, A. Gulieva,Sevgi Pekcan,Salih Uytun,Erkan Çakır,Bülent Karadağ,Pelin Asfuroğlu, Erdal Başaran,Velat Şen,Emre Demir, Veysel Karakulak,Sedat Öktem,Zeynep Seda Uyan,Yasemin Gökdemir, Fatma Telli Karakoç

Journal of Cystic Fibrosis（2023）

引用 0|浏览4

暂无评分

摘要

Modulatory therapies are not reimbursed by government in Turkey and approach to the treatment is currently available for three months only by court decision. In between the court decisions, most of the patients could not receive the treatment. So, these patients could not use the treatment continuously. The aim of the current study is to report the clinical characteristics of the patients and the results in patients.

查看译文

关键词

p173 modulatory therapy experience,cystic fibrosis,multi-centre

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要